Table 1.

Association of p16 expression (%positive cells) with demographic and clinical variables among women with atypia

p16 percentage of cells/positive
0%–10% (N = 158)11+% (N = 75)Pa
Age at BBD diagnosis0.0025
 <303 (100%)0 (%)
 30–398 (88.9%)1 (11.1%)
 40–4947 (82.5%)10 (17.5%)
 50–5940 (58%)29 (42%)
 60–6940 (72.7%)15 (27.3%)
 70+20 (50%)20 (50%)
Year of benign biopsy0.3588
 1967–19718 (88.9%)1 (11.1%)
 1972–197618 (78.3%)5 (21.7%)
 1977–198118 (62.1%)11 (37.9%)
 1982–198645 (70.3%)19 (29.7%)
 1987–199169 (63.9%)39 (36.1%)
Indication for biopsyb0.1738
 Lump70 (72.9%)26 (27.1%)
 Mammogram87 (64.4%)48 (35.6%)
Number of atypical foci0.6472
 1 focus90 (70.3%)38 (29.7%)
 2 foci42 (65.6%)22 (34.4%)
 3+ foci26 (63.4%)15 (36.6%)
Involutionc0.2132
 None12 (85.7%)2 (14.3%)
 Partial124 (67.8%)59 (32.2%)
 Complete19 (59.4%)13 (40.6%)
Family historyd0.5063
 No family history91 (68.4%)42 (31.6%)
 Weak family history22 (59.5%)15 (40.5%)
 Strong family history36 (70.6%)15 (29.4%)
Type of AH0.4596
 ADH63 (65.6%)33 (34.4%)
 ALH71 (67%)35 (33%)
 Both ADH and ALH24 (77.4%)7 (22.6%)
Follow-up, y0.5163
 Median (IQR)14.5 (9.0–18.1)14.7 (9.7–18.6)
  • aWilcoxon rank-sum test for follow-up in years, χ2 tests of statistical significance for all other variables.

  • bIndication for biopsy was available for 231 of 233 women.

  • cInvolution status was available for 229 of 233 women.

  • dFamily history of breast cancer was available for 221 of 233 women.